Bird & Bird secures a win before the UK High Court for Gilead

Bird & Bird’s London patent team has secured a win before the UK High Court for their client Gilead, a global pharmaceutical company known for its work in the medical fields of virology, oncology and inflammation.

On 21 March 2023, Mr Justice Meade held that two patents owned by the Defendant NuCana were invalid for added matter, lack of plausibility and insufficiency including on the basis of the undue burden involved in making the class of “2-methyl up 2-fluorine down” compounds, such as sofosbuvir, falling within the claims. Sofosbuvir is the key component of Gilead’s new class of anti-viral drugs (Solvaldi, Harvoni, Vosevi and Epclusa) that act as inhibitors of an essential enzyme of the Hepatitis C virus. The compound has achieved blockbuster status, with the capability to effectively cure Hepatitis C on a global scale.

In this judgment, the Judge not only considered plausibility, but also “implausibility”, in view of the upcoming decision of the EPO Enlarged Board of Appeal (G2/21, Sumitomo), which has the potential to change the way patentability is assessed in all areas of technology, and particularly the Life Sciences industry.

Bird & Bird’s team comprised IP partners Patrick Kelleher, Jennifer Jones as well as associates Henry Elliott, Ning-Ning Li, Patrick Brown and Josh Price.

News & Deals

More News & Deals

Deal

Bird & Bird advises Vanagon Ventures on seed investment in Particula

May 07 2025

Read More

Deal

Bird & Bird advises BRIDOR on its global bakery transaction in Australia

May 07 2025

Read More

News

Bird & Bird and the Finnish Olympic Committee Enter Partnership

May 07 2025

Read More

News

Bird & Bird strengthens Corporate team with new partner Shahin Foroughian in Singapore

May 07 2025

Read More

News

Bird & Bird hires three new partners into international Corporate Group

May 06 2025

Read More

Deal

Bird & Bird advises Gamma on its admission to the Main Market of the London Stock Exchange

May 02 2025

Read More